This UK multicentre study provides evidence that 24-weekly Decapeptyl SR is both efficacious and well-tolerated for the management of CPP, with comparable outcomes to the standard 12-weekly regimen. This is the first comparative analysis to establish clinical equivalence between these two regimens, which is particularly important given the reduced frequency of clinical monitoring in the longer-acting preparation. Fewer injections may improve adherence and patient satisfaction, alongside potential cost savings.
Varughese et al. (Fri,) studied this question.